Blog | HemaCare

Tests in New Immunotherapy Targets Macrophages Instead of Cancer Cells

Dec 23, 2019 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Macrophages, Immunotherapy (Immunology)

0 Comments

A collaborative team of scientists from Denmark, France, the UK, and the US recognized the potential to target CD163 macrophages for a novel approach to cancer immunotherapy.

Macrophages are one of many types of immune system cells of the body, and they function to phagocytize and digest invading substances including bacteria and other microorganisms; they also digest cellular debris and cancer cells. However, there are a subset of macrophages (CD163 macrophages) that actually supports tumor survival and impedes T-cell attack of tumors. Expression of CD163 by these macrophages is associated with a poorer prognosis for a number of human cancers, such as malignant melanoma.

Read More

University of Minnesota Opened New NK-Cell Immunotherapy Clinical Trial

Dec 3, 2019 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in NK Cells, Immunotherapy (Immunology)

0 Comments

The new FT516 immunotherapy is the first iPSC-derived therapy approved for clinical testing in the world and may provide a treatment for many different types of cancers.

A collaboration between the University of Minnesota and Fate Therapeutics will begin clinical trials for a novel “off-the-shelf” targeted natural killer (NK) cell cancer immunotherapy derived from induced pluripotent stem cells (iPSCs). iPSCs are adult cells that have been genetically reprogrammed so that they regain the ability to differentiate into any cell type, making them pluripotent (similar to embryonic stem cells). The new NK cell therapy, FT516, is developed from genetically engineered human iPSCs with enhanced anti-tumor activity.

Read More

Immunotherapy for Breast Cancer on the Horizon

Sep 17, 2019 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Tumors, Immunotherapy (Immunology)

0 Comments

A new treatment has been approved by the FDA to treat breast cancer that combines chemotherapy with immunotherapy.

The war against cancer is ongoing and consists of both winning and losing battles. There are several cancers that have been successfully treated with immunotherapy. However, one type of cancer has been a challenge for the application of immunotherapy is breast cancer. There are various subtypes of breast cancer, and each requires a different treatment approach due to the distinct biology associated with these cancer types and the specific mechanisms involved in breast tumor development.

Read More

Can TRuCs Beat CARs?

Jul 30, 2019 10:08:00 AM / by Nancy Andon, MSc posted in CAR-T, T Cells, Immunotherapy (Immunology)

0 Comments

Exciting new research published in Nature Communications cites using HemaCare leukapheresis material to design primary human T cells that may be more effective at fighting cancer than CAR-T cells. [1]

The successful treatment of B cell leukemias with genetically modified T cells heralded a new frontier in cell-based medicines. CAR-T cells, or chimeric antigen receptor T cells, have become the face of cell and gene therapy, with Novartis’ first-in-class Kymriah® prompting a robust pipeline of competitive CAR-T treatments. Now a research group in Cambridge, Massachusetts is taking T cell-based immunotherapy one step further. By changing the way T cells target cancer cells, they claim to have come up with a more effective cancer immunotherapy mechanism.

Read More

NK Cell Clinical Trial Begins for Incurable Cancer

Jul 16, 2019 10:12:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, NK Cells, Immunotherapy (Immunology)

0 Comments

New tests begin in the United States using stem cell-derived natural killer cells to help patients suffering from incurable cancer.

Curing the incurable is an ongoing and top endeavor in medical research. This is particularly true for the various forms of cancer that are difficult to treat. The investigation and use of immunotherapy as an option for the treatment of different forms of cancer continues to increase. The main immunotherapeutic approach to cancer involves harvesting stem cells from the patient or a donor. Given the logistics, cost, and time this approach takes, the development of a strategy or cell products that can be used on demand is much desired.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts